ArticleExperimental and therapeutic medicine2011

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer.

Akira Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.